Abivax (ABVX) EBIT (2024 - 2026)

Abivax's EBIT history runs 3 years deep, the most recent figure standing at -$65.8 million for Q1 2026.

• In Q1 2026, EBIT fell 32.59% year-over-year to -$65.8 million; the TTM figure through Mar 2026 stood at -$296.3 million (down 57.12% YoY), while the FY2025 annual figure was -$286.5 million, down 54.96% from the prior year.
• EBIT was -$65.8 million for Q1 2026 at Abivax, up from -$83.5 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$38.0 million in Q2 2024 to a low of -$94.4 million in Q3 2025.
• Historically, EBIT has averaged -$59.3 million across 3 years, with a median of -$52.6 million in 2025.
• Biggest YoY gain for EBIT was 2.31% in 2025; the steepest drop was 82.41% in 2025.
• A 3-year view of EBIT shows it stood at -$45.8 million in 2024, then sank by 82.41% to -$83.5 million in 2025, then climbed by 21.12% to -$65.8 million in 2026.
• The last three EBIT figures came in at -$65.8 million (Q1 2026), -$83.5 million (Q4 2025), and -$94.4 million (Q3 2025), per Business Quant data.